MAPT and Alzheimer disease: Critically, if some degree of the cognitive impairment seen in AD is due to diet-modifiable factors, as opposed to amyloid-beta (Aβ) and tau pathology and cell death, then interventions could realistically improve cognition and quality of life in a way that is not currently possible with traditional AD treatments.